Methods and kits for detecting urinary tract infections

By using antibiotics and antifungal agents in covered, transparent or semi-transparent sterile containers, and comparing changes in urine turbidity before and after incubation, the challenges of urinary tract infection detection and drug sensitivity assessment have been solved, improving the diagnosis and treatment of urinary tract infections.

CN123125339APending Publication Date: 2026-11-17IMMUNOGENETICS LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202580025033.8
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2024-02-13
Filing Date
2025-02-12
Publication Date
2026-11-17

AI Technical Summary

Technical Problem

Existing technologies are insufficient for the rapid and accurate detection of urinary tract infections and the determination of the sensitivity of the bacteria or fungi causing the infection to antibiotics and antifungal agents, leading to poor treatment outcomes or delays in treatment.

Method used

A kit is provided comprising a covered, transparent or semi-transparent sterile container containing antibiotics and/or antifungal agents, which allows for the determination of infection type and drug sensitivity by incubating urine in separate containers and comparing changes in turbidity.

Benefits of technology

It enables rapid and convenient diagnosis of urinary tract infections and assessment of the sensitivity of infectious microorganisms to drugs, improving the accuracy and efficiency of treatment.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

This disclosure provides a kit for detecting urinary tract infections in subjects. Methods for diagnosing urinary tract infections in subjects and determining the susceptibility of the bacteria and / or fungi causing the urinary tract infection to antibiotics and / or antifungal agents are also provided.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] Cross-references to related applications

[0002] This application claims priority to U.S. Provisional Patent Application No. 63 / 552,917, filed February 13, 2024, the entire contents of which are incorporated herein by reference. Technical Field

[0003] This disclosure relates to kits and methods for detecting urinary tract infections in subjects and determining the susceptibility of the bacteria and / or fungi causing the urinary tract infection to antibiotics and / or antifungal agents. Background Technology

[0004] Urinary tract infection (UTI) is one of the most common types of infection, causing more than 8 million visits to healthcare providers in the United States each year. UTI can affect any part of the urinary system, including the kidneys, ureters, urethra, and bladder. Complications of UTI can include severe kidney damage, recurrent UTI, preterm birth in pregnant women, and sepsis. Therefore, there is a need to develop diagnostic tests for the early detection of UTI. Summary of the Invention

[0005] This document provides a kit comprising: (a) a first covered transparent or semi-transparent sterile container; and (b) a second covered transparent or semi-transparent sterile container, the second container containing at least one antibiotic and / or at least one antifungal agent.

[0006] In some embodiments of any of the kits described herein, the first capped transparent or semi-transparent sterile container and the second capped transparent or semi-transparent sterile container are made of glass. In some embodiments of any of the kits described herein, the first capped transparent or semi-transparent sterile container and the second capped transparent or semi-transparent sterile container are made of plastic.

[0007] In some embodiments of any of the kits described herein, the first covered transparent or semi-transparent sterile container and the second covered transparent or semi-transparent sterile container are flat-bottomed containers. In some embodiments of any of the kits described herein, the first covered transparent or semi-transparent sterile container and the second covered transparent or semi-transparent sterile container are round-bottomed containers.

[0008] In some embodiments of any of the kits described herein, the first and second covered transparent or semi-transparent sterile containers comprise screw caps. In some embodiments of any of the kits described herein, the screw caps comprise filters or membranes with a pore size of about 0.03 micrometers to about 0.22 micrometers, the filters or membranes allowing air to enter and exit the first and second covered transparent or semi-transparent sterile containers. In some embodiments of any of the kits described herein, the first and second covered transparent or semi-transparent sterile containers comprise snap-on caps. In some embodiments of any of the kits described herein, the snap-on caps comprise filters or membranes with a pore size of about 0.03 micrometers to about 0.22 micrometers, the filters or membranes allowing air to enter and exit the first and second covered transparent or semi-transparent sterile containers.

[0009] In some embodiments of any of the kits described herein, the internal volume of the first capped transparent or semi-transparent sterile container and the second capped transparent or semi-transparent sterile container is from about 0.2 mL to about 50 mL. In some embodiments of any of the kits described herein, the internal volume of the first capped transparent or semi-transparent sterile container and the second capped transparent or semi-transparent sterile container is from about 0.5 mL to about 20 mL. In some embodiments of any of the kits described herein, the internal volume of the first capped transparent or semi-transparent sterile container and the second capped transparent or semi-transparent sterile container is from about 1 mL to about 5 mL.

[0010] In some embodiments of any of the kits described herein, the height of the first and second covered transparent or semi-transparent sterile containers is from about 1.0 cm to about 20 cm. In some embodiments of any of the kits described herein, the height of the first and second covered transparent or semi-transparent sterile containers is from about 1.5 cm to about 15 cm. In some embodiments of any of the kits described herein, the height of the first and second covered transparent or semi-transparent sterile containers is from about 2 cm to about 10 cm.

[0011] In some embodiments of any of the kits described herein, the second capped transparent or semi-transparent sterile container contains at least one antibiotic. In some embodiments of any of the kits described herein, the at least one antibiotic is present as a solid in the second capped transparent or semi-transparent sterile container. In some embodiments of any of the kits described herein, the at least one antibiotic is present as a solution in the second capped transparent or semi-transparent sterile container.

[0012] In some embodiments of any of the kits described herein, the at least one antibiotic is selected from: amoxicillin / clavulanic acid, ampicillin, ampicillin / sulbactam, cefazolin, cefepime, ceftriaxone, ciprofloxacin, ertapenem, fosfomycin, gentamicin, imipenem, levofloxacin, nitrofurantoin, PIP / tazobactam, tobramycin, and trimethoprim / sulfamethoxazole.

[0013] In some embodiments of any kit described herein, the at least one antibiotic is a single antibiotic. In some embodiments of any kit described herein, the at least one antibiotic is two or more different antibiotics.

[0014] In some embodiments of any of the kits described herein, the second capped transparent or translucent sterile container contains at least one antifungal agent. In some embodiments of any of the kits described herein, the at least one antifungal agent is present as a solid in the second capped transparent or translucent sterile container. In some embodiments of any of the kits described herein, the at least one antifungal agent is present as a solution in the second capped transparent or translucent sterile container.

[0015] In some embodiments of any of the kits described herein, the at least one antifungal agent is selected from: fluconazole, caspofungin, anidoxuridine, voriconazole, amphotericin B, echinococcin, and azoles.

[0016] In some embodiments of any kit described herein, the at least one antifungal agent is a single antifungal agent. In some embodiments of any kit described herein, the at least one antifungal agent is two or more different antifungal agents. In some embodiments of any kit described herein, the second capped transparent or translucent sterile container contains at least one antibiotic and at least one antifungal agent.

[0017] In some embodiments of any of the kits described herein, the kit includes a scaffold.

[0018] In some embodiments of any of the kits described herein, the kit includes at least one additional covered transparent or semi-transparent sterile container containing at least one antibiotic and / or at least one antifungal agent, the antibiotic and / or antifungal agent being different from the at least one antibiotic and / or at least one antifungal agent present in the second covered transparent or semi-transparent sterile container.

[0019] This article also provides a method for diagnosing a urinary tract infection in a subject and determining the susceptibility of the bacteria and / or fungi causing the urinary tract infection to antibiotics and / or antifungal agents, wherein the method comprises: (a) placing a volume of urine from the subject into a first covered transparent or semi-transparent sterile container; (b) placing a volume of urine from the subject into a second covered transparent or semi-transparent sterile container, the second container containing at least one antibiotic and / or at least one antifungal agent; (c) incubating the first covered transparent or semi-transparent sterile container and the second covered transparent or semi-transparent sterile container for a specified time period; (d) The turbidity of the urine in the first and second covered transparent or semi-transparent sterile containers was determined after the specified time period; wherein: the presence of turbidity in the urine in the first covered transparent or semi-transparent sterile container after the specified time period indicates that the subject has a urinary tract infection, and a decrease in turbidity of the urine in the second covered transparent or semi-transparent container compared to the turbidity of the urine in the first covered transparent or semi-transparent sterile container after the specified time period indicates treatment of the bacteria or fungus causing the urinary tract infection with at least one antibiotic and / or at least one antifungal agent present in the second covered transparent or semi-transparent sterile container. Sensitivity; the presence of turbidity in the urine in the first covered transparent or semi-transparent sterile container indicates that the subject has a urinary tract infection, and the similarity of turbidity in the urine in the second covered transparent or semi-transparent container to the turbidity in the urine in the first covered transparent or semi-transparent sterile container after the time period indicates that the bacteria or fungus causing the infection is not sensitive to treatment with the at least one antibiotic and / or the at least one antifungal agent present in the second covered transparent or semi-transparent sterile container; or the lack of detectable turbidity in the urine in the first covered transparent or semi-transparent sterile container after the time period indicates that the subject does not have a urinary tract infection.

[0020] In some embodiments of any of the methods described herein, the method further includes collecting urine from the subject. In some embodiments of any of the methods described herein, the placement in steps (a) and (b) includes using a pipette. In some embodiments of any of the methods described herein, the pipette is a disposable plastic pipette. In some embodiments of any of the methods described herein, the method further includes, between steps (c) and (d), shaking the first capped transparent or translucent sterile container and the second capped transparent or translucent sterile container.

[0021] In some embodiments of any of the methods described herein, the subject is identified as having a urinary tract infection, and the bacteria or fungus causing the urinary tract infection is identified as sensitive to treatment with the at least one antibiotic and / or the at least one antifungal agent present in the second covered transparent or semi-transparent sterile container. In some embodiments of any of the methods described herein, the subject is identified as having a urinary tract infection, and the bacteria or fungus causing the urinary tract infection is identified as insensitive to treatment with the at least one antibiotic and / or the at least one antifungal agent present in the second covered transparent or semi-transparent sterile container.

[0022] In some implementations of any of the methods described herein, the subject was identified as not having a urinary tract infection.

[0023] In some embodiments of any of the methods described herein, the method includes informing a physician that the subject has been diagnosed with a urinary tract infection. In some embodiments of any of the methods described herein, the method includes informing a physician that the subject has been diagnosed with a urinary tract infection, and that the bacteria or fungus causing the urinary tract infection has been identified as sensitive to treatment with at least one antibiotic and / or at least one antifungal agent present in the second covered transparent or semi-transparent sterile container. In some embodiments of any of the methods described herein, the method includes informing a physician that the subject has been diagnosed with a urinary tract infection, and that the bacteria or fungus causing the urinary tract infection has been identified as unsensitive to treatment with at least one antibiotic and / or at least one antifungal agent present in the second covered transparent or semi-transparent sterile container.

[0024] In some embodiments of any of the methods described herein, the time period is from about 6 hours to about 48 hours. In some embodiments of any of the methods described herein, the time period is from about 12 hours to about 48 hours. In some embodiments of any of the methods described herein, the time period is from about 12 hours to about 36 hours.

[0025] In some embodiments of any of the methods described herein, the incubation in steps (c) and (d) is performed at a temperature of about 22°C to about 37°C. In some embodiments of any of the methods described herein, the incubation in steps (c) and (d) is performed at a temperature of about 22°C to about 30°C. In some embodiments of any of the methods described herein, the incubation in steps (c) and (d) is performed at a temperature of about 22°C to about 26°C.

[0026] In some embodiments of any of the methods described herein, the first covered transparent or translucent sterile container and the second covered transparent or translucent sterile container are made of glass. In some embodiments of any of the methods described herein, the first covered transparent or translucent sterile container and the second covered transparent or translucent sterile container are made of plastic.

[0027] In some embodiments of any of the methods described herein, the first covered transparent or semi-transparent sterile container and the second covered transparent or semi-transparent sterile container are flat-bottomed containers. In some embodiments of any of the methods described herein, the first covered transparent or semi-transparent sterile container and the second covered transparent or semi-transparent sterile container are round-bottomed containers.

[0028] In some embodiments of any of the methods described herein, the first and second covered transparent or semi-transparent sterile containers comprise screw caps. In some embodiments of any of the methods described herein, the screw caps comprise filters or membranes with a pore size of about 0.03 micrometers to about 0.22 micrometers, the filters or membranes allowing air to enter and exit the first and second covered transparent or semi-transparent sterile containers. In some embodiments of any of the methods described herein, the first and second covered transparent or semi-transparent sterile containers comprise snap-on caps. In some embodiments of any of the methods described herein, the snap-on caps comprise filters or membranes with a pore size of about 0.03 micrometers to about 0.22 micrometers, the filters or membranes allowing air to enter and exit the first and second covered transparent or semi-transparent sterile containers.

[0029] In some embodiments of any of the methods described herein, the internal volume of the first capped transparent or semi-transparent sterile container and the second capped transparent or semi-transparent sterile container is from about 0.2 mL to about 50 mL. In some embodiments of any of the methods described herein, the internal volume of the first capped transparent or semi-transparent sterile container and the second capped transparent or semi-transparent sterile container is from about 0.5 mL to about 20 mL. In some embodiments of any of the methods described herein, the internal volume of the first capped transparent or semi-transparent sterile container and the second capped transparent or semi-transparent sterile container is from about 1 mL to about 5 mL.

[0030] In some embodiments of any of the methods described herein, the height of the first covered transparent or semi-transparent sterile container and the second covered transparent or semi-transparent sterile container is from about 1.0 cm to about 20 cm. In some embodiments of any of the methods described herein, the height of the first covered transparent or semi-transparent sterile container and the second covered transparent or semi-transparent sterile container is from about 1.5 cm to about 15 cm. In some embodiments of any of the methods described herein, the height of the first covered transparent or semi-transparent sterile container and the second covered transparent or semi-transparent sterile container is from about 2 cm to about 10 cm.

[0031] In some embodiments of any of the methods described herein, the second capped transparent or translucent sterile container contains at least one antibiotic. In some embodiments of any of the methods described herein, the at least one antibiotic is present as a solid in the second capped transparent or translucent sterile container. In some embodiments of any of the methods described herein, the at least one antibiotic is present as a solution in the second capped transparent or translucent sterile container.

[0032] In some embodiments of any of the methods described herein, the at least one antibiotic is selected from: amoxicillin / clavulanic acid, ampicillin, ampicillin / sulbactam, cefazolin, cefepime, ceftriaxone, ciprofloxacin, ertapenem, fosfomycin, gentamicin, imipenem, levofloxacin, nitrofurantoin, PIP / tazobactam, tobramycin, and trimethoprim / sulfamethoxazole.

[0033] In some embodiments of any of the methods described herein, the at least one antibiotic is a single antibiotic. In some embodiments of any of the methods described herein, the at least one antibiotic is two or more different antibiotics.

[0034] In some embodiments of any of the methods described herein, the second covered transparent or translucent sterile container contains at least one antifungal agent. In some embodiments of any of the methods described herein, the at least one antifungal agent is present as a solid in the second covered transparent or translucent sterile container. In some embodiments of any of the methods described herein, the at least one antifungal agent is present as a solution in the second covered transparent or translucent sterile container.

[0035] In some embodiments of any of the methods described herein, the at least one antifungal agent is selected from: fluconazole, caspofungin, anidoxuridine, voriconazole, amphotericin B, echinococcin, and azoles.

[0036] In some embodiments of any of the methods described herein, the at least one antifungal agent is a single antifungal agent. In some embodiments of any of the methods described herein, the at least one antifungal agent is two or more different antifungal agents.

[0037] In some embodiments of any of the methods described herein, the second covered transparent or translucent sterile container contains at least one antibiotic and at least one antifungal agent.

[0038] definition

[0039] As used herein, the term "about" is used to mean approximately, around, roughly, or roughly. When the term "about" is used in conjunction with a numerical range, it modifies the range by extending the upper and lower boundaries of the value. Typically, the term "about" is used herein to modify values ​​above and below the value by a difference of 10%.

[0040] As used herein, the term "subject" can refer to both humans and non-human animals. Non-human animals can include vertebrates, such as mammals and non-mammals, such as non-human primates, sheep, cats, horses, cattle, dogs, mice, rats, goats, rabbits, and pigs. For example, a subject can be a human.

[0041] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention pertains. This document describes the methods and materials used in this invention; other suitable methods and materials known in the art may also be used. The materials, methods, and examples described are merely illustrative and not intended to be limiting. All publications, patent applications, patents, sequences, database entries, and other references mentioned herein are incorporated herein by reference in their entirety. In the event of conflict, this specification, including the definitions, shall prevail.

[0042] Other features and advantages of the invention will become clear from the following detailed description, the accompanying drawings, and the claims. Detailed Implementation

[0043] Urinary tract infection (UTI) is one of the most common types of infection, placing a significant burden on the healthcare system. UTI can affect any part of the urinary system, including the kidneys, ureters, urethra, and bladder, and if left untreated, can lead to complications such as serious kidney damage, recurrent UTI, premature birth in pregnant women, and sepsis.

[0044] Reagent test kit

[0045] This disclosure provides kits comprising a covered transparent or semi-transparent sterile container (e.g., a first covered transparent or semi-transparent sterile container and a second covered transparent or semi-transparent sterile container). Such kits may further comprise at least one antibiotic, at least one antifungal agent, at least one pH-sensitive dye, or a combination thereof. In some embodiments, kits are provided herein comprising: (a) a first covered transparent or semi-transparent sterile container; and (b) a second covered transparent or semi-transparent sterile container, the second container comprising at least one antibiotic and / or at least one antifungal agent. In some embodiments, the first covered transparent or semi-transparent sterile container and / or the second covered transparent or semi-transparent sterile container further comprise at least one pH-sensitive dye (e.g., any exemplary pH-sensitive dye described herein or known in the art).

[0046] sterile containers

[0047] The covered transparent or semi-transparent sterile container (e.g., a first covered transparent or semi-transparent sterile container and / or a second covered transparent or semi-transparent sterile container) can be of any suitable shape and made of any suitable material described herein or known in the art. For example, the covered transparent or semi-transparent sterile container can be made of glass (e.g., borosilicate glass or fused silica) and / or plastic (e.g., polypropylene or polystyrene). In some embodiments, the covered transparent or semi-transparent sterile container is a flat-bottomed container. In some embodiments, the covered transparent or semi-transparent sterile container is a round-bottomed container.

[0048] The lid of the covered transparent or semi-transparent sterile container (e.g., a first covered transparent or semi-transparent sterile container and / or a second covered transparent or semi-transparent sterile container) can be any suitable lid described herein or known in the art. For example, the lid can be a screw cap or a snap-on cap.

[0049] In some embodiments, the cover described herein may comprise a filter or membrane (e.g., a polycarbonate membrane or PVDF). In some embodiments, the cover comprises a filter or membrane with a pore size of about 0.03 micrometers to about 0.22 micrometers. For example, the pore size of the filter or membrane may be about 0.03 micrometers to about 0.18 micrometers, about 0.03 micrometers to about 0.14 micrometers, about 0.03 micrometers to about 0.10 micrometers, about 0.03 micrometers to about 0.06 micrometers, about 0.06 micrometers to about 0.22 micrometers, about 0.06 micrometers to about 0.18 micrometers, about 0.06 micrometers to about 0.14 micrometers, about 0.06 micrometers to about 0.10 micrometers, about 0.10 micrometers to about 0.22 micrometers, about 0.10 micrometers to about 0.18 micrometers, about 0.10 micrometers to about 0.14 micrometers, about 0.14 micrometers to about 0.22 micrometers, about 0.14 micrometers to about 0.18 micrometers, or about 0.18 micrometers to about 0.22 micrometers. In some embodiments, the filter or membrane has a pore size of about 0.03 micrometers, about 0.06 micrometers, about 0.10 micrometers, about 0.18 micrometers, or about 0.22 micrometers. In some embodiments, the filter or membrane allows air to enter and exit the covered transparent or translucent sterile container (e.g., the first covered transparent or translucent sterile container and / or the second covered transparent or translucent sterile container).

[0050] In some embodiments, the internal volume of the capped transparent or semi-transparent sterile container (e.g., a first capped transparent or semi-transparent sterile container and / or a second capped transparent or semi-transparent sterile container) is from about 0.2 mL to about 50 mL. For example, the internal volume of a capped transparent or translucent sterile container can be from about 0.2 mL to about 45 mL, from about 0.2 mL to about 40 mL, from about 0.2 mL to about 35 mL, from about 0.2 mL to about 30 mL, from about 0.2 mL to about 25 mL, from about 0.2 mL to about 20 mL, from about 0.2 mL to about 15 mL, from about 0.2 mL to about 10 mL, from about 0.2 mL to about 5 mL, from about 0.2 mL to about 1 mL, from about 0.2 mL to about 0.5 mL, from about 0.5 mL to about 50 mL, from about 0.5 mL to about 45 mL, from about 0.5 mL to about 40 mL, from about 0.5 mL to about 35 mL, from about 0.5 mL to about 30 mL, from about 0.5 mL to about 25 mL, from about 0.5 mL to about 20 mL, from about 0.5 mL to about 15 mL, from about 0.5 mL to about 10 mL, from about 0.5 mL to about 5 mL, from about 0.5 mL to 1 mL, about 1 mL to 50 mL, about 1 mL to 45 mL, about 1 mL to 40 mL, about 1 mL to 35 mL, about 1 mL to 30 mL, about 1 mL to 25 mL, about 1 mL to 20 mL, about 1 mL to 15 mL, about 1 mL to 10 mL, about 1 mL to 5 mL, about 5 mL to 50 mL, about 5 mL to 45 mL, about 5 mL to 40 mL, about 5 mL to 35 mL, about 5 mL to 30 mL, about 5 mL to 25 mL, about 5 mL to 20 mL, about 5 mL to 15 mL, about 5 mL to 10 mL, about 10 mL to 50 mL, about 10 mL to 45 mL, about 10 mL to 40 mL, about 10 mL to 35 mL, about 10 mL to 30 mL, about 10 mL to 25 mL, about 10 mL to 20 mL, about 10 mL to 15 mL, about 15 mL to 50 mL, about 15 mL to 45 mL mL, about 15 mL to about 40 mL, about 15 mL to about 35 mL, about 15 mL to about 30 mL, about 15 mL to about 25 mL, about 15 mL to about 20 mL, about 20 mL to about 50 mL, about 20 mL to about 45 mL, about 20 mL to about 40 mL, about 20 mL to about 35 mL, about 20 mL to about 30 mL, about 20 mL to about 25 mL, about 25 mL to about 50 mL, about 25 mL to about 45 mL, about 25 mL to about 40 mL, about 25 mL to about 35 mL, about 25 mL to about 30 mL, about 30 mL to about 50 mL, about 30 mL to about 45 mL, about 30 mL to about 40 mL, about 30 mL to about 35 mL, about 35 mL to about 50 mL, about 35 mL to about 45 mL, about 35 mL to about 40 mL, about 40 mL to about 50 mL, about 40 mL to about 45 mL or about 45 mL to about 50 mL. In some embodiments, the internal volume of the capped transparent or semi-transparent sterile container is about 0.2 mL, about 0.5 mL, about 1 mL, about 5 mL, about 10 mL, about 15 mL, or about 20 mL. In some embodiments, the internal volume of the capped transparent or semi-transparent sterile container is from about 0.5 mL to about 20 mL. In some embodiments, the internal volume of the capped transparent or semi-transparent sterile container is from about 1 mL to about 5 mL.

[0051] In some embodiments, the height of the covered transparent or semi-transparent sterile container (e.g., a first covered transparent or semi-transparent sterile container and / or a second covered transparent or semi-transparent sterile container) is from about 1.0 cm to about 20 cm. For example, the height of a covered transparent or translucent sterile container can be approximately 1 cm to 20 cm, approximately 1 cm to 18 cm, approximately 1 cm to 16 cm, approximately 1 cm to 14 cm, approximately 1 cm to 12 cm, approximately 1 cm to 10 cm, approximately 1 cm to 8 cm, approximately 1 cm to 6 cm, approximately 1 cm to 4 cm, approximately 1 cm to 2 cm, approximately 1 cm to 1.5 cm, approximately 1.5 cm to 20 cm, approximately 1.5 cm to 18 cm, approximately 1.5 cm to 16 cm, approximately 1.5 cm to 14 cm, approximately 1.5 cm to 15 cm, approximately 1.5 cm to 12 cm, approximately 1.5 cm to 10 cm, approximately 1.5 cm to 8 cm, approximately 1.5 cm to 6 cm, approximately 1.5 cm to 4 cm, approximately 1.5 cm to 2 cm, approximately 2 cm to 20 cm, approximately 2 cm to 18 cm, approximately 2 cm to 16 cm, approximately 2 cm to 14 cm, approximately 2 cm to 12 cm, approximately 2 cm to about 10 cm, about 2 cm to about 8 cm, about 2 cm to about 6 cm, about 2 cm to about 4 cm, about 4 cm to about 20 cm, about 4 cm to about 18 cm, about 4 cm to about 16 cm, about 4 cm to about 14 cm, about 4 cm to about 12 cm, about 4 cm to about 10 cm, about 4 cm to about 8 cm, about 4 cm to about 6 cm, about 6 cm to about 20 cm, about 6 cm to about 18 cm, about 6 cm to about 16 cm, about 6 cm to about 14 cm, about 6 cm to about 12 cm, about 6 cm to about 10 cm, about 6 cm to about 8 cm, about 8 cm to about 20 cm, about 8 cm to about 18 cm, about 8 cm to about 16 cm, about 8 cm to about 14 cm, about 8 cm to about 12 cm, about 8 cm to about 10 cm, about 10 cm to about 20 cm, about 10 cm to about 18 cm, about 10 cm to about 16 cm, about 10 cm to about 14 cm, about 10 cm to about 12 cm, about 12 cm to about 20 cm cm, about 12 cm to about 18 cm, about 12 cm to about 16 cm, about 12 cm to about 14 cm, about 14 cm to about 20 cm, about 14 cm to about 18 cm, about 14 cm to about 16 cm, about 16 cm to about 20 cm, about 16 cm to about 18 cm or about 18 cm to about 20 cm.In some embodiments, the height of the covered transparent or semi-transparent sterile container is from about 1.5 cm to about 15 cm. In some embodiments, the height of the covered transparent or semi-transparent sterile container is from about 2 cm to about 10 cm. In some embodiments, the height of the covered transparent or semi-transparent sterile container is about 1.0 cm, about 1.5 cm, about 2 cm, about 4 cm, about 6 cm, about 8 cm, about 10 cm, about 12 cm, about 14 cm, about 16 cm, about 18 cm, or about 20 cm.

[0052] antibiotics and antifungal agents

[0053] In some embodiments, a covered transparent or semi-transparent sterile container (e.g., a second covered transparent or semi-transparent sterile container) contains at least one antibiotic. The at least one antibiotic may be present in the covered transparent or semi-transparent sterile container (e.g., the second covered transparent or semi-transparent sterile container) as a solid or as a solution. Non-limiting examples of antibiotics that may be present in the covered transparent or semi-transparent sterile containers described herein include amoxicillin / clavulanic acid, ampicillin, ampicillin / sulbactam, cefazolin, cefepime, ceftriaxone, ciprofloxacin, ertapenem, fosfomycin, gentamicin, imipenem, levofloxacin, nitrofurantoin, PIP / tazobactam, tobramycin, and trimethoprim / sulfamethoxazole. In some embodiments, the at least one antibiotic is a single antibiotic. In some embodiments, the at least one antibiotic is two or more different antibiotics (e.g., two, three, four, five, six, or more different antibiotics).

[0054] In some embodiments, the covered transparent or semi-transparent sterile container described herein (e.g., a second covered transparent or semi-transparent sterile container) contains at least one antifungal agent. The at least one antifungal agent may be present in the covered transparent or semi-transparent sterile container (e.g., the second covered transparent or semi-transparent sterile container) as a solid or as a solution. Non-limiting examples of antifungal agents that may be present in the covered transparent or semi-transparent sterile containers described herein include fluconazole, caspofungin, anisofungin, voriconazole, amphotericin B, echinococcin, and azoles. In some embodiments, the at least one antifungal agent is a single antifungal agent. In some embodiments, the at least one antifungal agent is two or more different antifungal agents (e.g., two, three, four, five, six, or more different antifungal agents).

[0055] In some embodiments, a covered transparent or semi-transparent sterile container (e.g., a second covered transparent or semi-transparent sterile container) contains at least one antibiotic and at least one antifungal agent.

[0056] In some embodiments, the kit described herein further comprises at least one additional capped transparent or translucent sterile container containing at least one antibiotic and / or at least one antifungal agent, said additional container being different from said at least one antibiotic and / or said at least one antifungal agent present in the second capped transparent or translucent sterile container. In some embodiments, the kit described herein further comprises a support.

[0057] pH-sensitive dyes

[0058] In some embodiments, a covered transparent or semi-transparent sterile container (e.g., a first covered transparent or semi-transparent sterile container) contains at least one pH-sensitive dye. Non-limiting examples of pH-sensitive dyes include litmus, phenolphthalein, and phenol red.

[0059] method

[0060] This article also provides methods for diagnosing urinary tract infections in subjects and determining the susceptibility of the bacteria and / or fungi causing the urinary tract infections to antibiotics and / or antifungal agents.

[0061] In some embodiments, the method provided herein includes (a) placing a volume of urine from a subject into a first covered transparent or semi-transparent sterile container (e.g., any first covered transparent or semi-transparent sterile container described herein); (b) placing a volume of urine from the subject into a second covered transparent or semi-transparent sterile container (e.g., any second covered transparent or semi-transparent sterile container described herein), the second container containing at least one antibiotic and / or at least one antifungal agent (e.g., any antibiotic and / or antifungal agent described herein); (c) incubating the first covered transparent or semi-transparent sterile container and the second covered transparent or semi-transparent sterile container for a certain period of time; and (d) determining the turbidity of the urine in the first covered transparent or semi-transparent sterile container and the second covered transparent or semi-transparent sterile container after the period of time. In some embodiments, the method further includes placing a volume of urine from the subject into at least one additional covered transparent or semi-transparent sterile container containing at least one antibiotic and / or at least one antifungal agent, the antibiotic and / or antifungal agent being different from the at least one antibiotic and / or at least one antifungal agent present in the second covered transparent or semi-transparent sterile container.

[0062] The presence or absence of turbidity in the urine can be used to identify a subject with a urinary tract infection. For example, the presence of turbidity in the urine in the first covered transparent or semi-transparent sterile container after the stated time period may indicate that the subject has a urinary tract infection. In some embodiments, the absence of detectable turbidity in the urine in the first covered transparent or semi-transparent sterile container after the stated time period indicates that the subject does not have a urinary tract infection.

[0063] In some embodiments, a decrease in turbidity of the urine in the second covered transparent or semi-transparent container compared to the turbidity of the urine in the first covered transparent or semi-transparent sterile container after the specified time period indicates that the bacteria or fungus causing the urinary tract infection is sensitive to treatment with at least one antibiotic and / or at least one antifungal agent present in the second covered transparent or semi-transparent sterile container. In some embodiments, a similar turbidity of the urine in the second covered transparent or semi-transparent container compared to the turbidity of the urine in the first covered transparent or semi-transparent sterile container after the specified time period indicates that the bacteria or fungus causing the infection is not sensitive to treatment with at least one antibiotic and / or at least one antifungal agent present in the second covered transparent or semi-transparent sterile container.

[0064] In some embodiments, the subject is identified as having a urinary tract infection, and the bacteria or fungus causing the urinary tract infection is identified as sensitive to treatment with at least one antibiotic and / or at least one antifungal agent present in the second covered transparent or semi-transparent sterile container. In some embodiments, the subject is identified as having a urinary tract infection, and the bacteria or fungus causing the urinary tract infection is identified as sensitive to treatment with at least one antibiotic and / or at least one antifungal agent present in the at least one additional covered transparent or semi-transparent sterile container.

[0065] In some embodiments, the subject is identified as having a urinary tract infection, and the bacteria or fungus causing the urinary tract infection is identified as insensitive to treatment with the at least one antibiotic and / or the at least one antifungal agent present in the second covered transparent or semi-transparent sterile container. In some embodiments, the subject is identified as having a urinary tract infection, and the bacteria or fungus causing the urinary tract infection is identified as insensitive to treatment with the at least one antibiotic and / or the at least one antifungal agent present in the at least one additional covered transparent or semi-transparent sterile container.

[0066] In some implementations, the subject is identified as not having a urinary tract infection.

[0067] In some embodiments, the method provided herein includes (a) placing a volume of urine from a subject into a first covered transparent or semi-transparent sterile container (e.g., any first covered transparent or semi-transparent sterile container described herein), the first container containing at least one pH-sensitive dye (e.g., any pH-sensitive dye described herein); (b) placing a volume of urine from the subject into a second covered transparent or semi-transparent sterile container (e.g., any second covered transparent or semi-transparent sterile container described herein), the second container containing at least one antibiotic and / or at least one antifungal agent (e.g., any antibiotic and / or antifungal agent described herein) and the at least one pH-sensitive dye; (c) incubating the first covered transparent or semi-transparent sterile container and the second covered transparent or semi-transparent sterile container for a specified time period; (d) After the stated time period, the color change of the urine in the first and second covered transparent or semi-transparent sterile containers was determined compared to a control covered transparent or semi-transparent container containing sterile water or a pH-neutral buffer solution (pH 6 to 8) and the at least one pH-sensitive dye. A significant color change in the urine in the first covered transparent or semi-transparent sterile container after the stated time period indicated that the subject had a urinary tract infection, and no significant color change in the urine in the second covered transparent or semi-transparent container after the stated time period compared to the control covered transparent or semi-transparent container indicated that the bacteria or fungus causing the urinary tract infection were resistant to the at least one antibiotic present in the second covered transparent or semi-transparent sterile container. The subject is sensitive to the treatment of antibiotics and / or at least one antifungal agent; a significant color change in the urine in the first covered transparent or semi-transparent sterile container indicates that the subject has a urinary tract infection, and a significant color change in the urine in the second covered transparent or semi-transparent container after the time period compared to the control covered transparent or semi-transparent container after the time period indicates that the bacteria or fungus causing the infection is not sensitive to the treatment of at least one antibiotic and / or at least one antifungal agent present in the second covered transparent or semi-transparent sterile container; or no significant color change in the urine in the first covered transparent or semi-transparent sterile container after the time period compared to the covered transparent or semi-transparent container indicates that the subject does not have a urinary tract infection. As used herein, a pH-sensitive dye means a dye that changes color when the pH changes from 6-8 to less than 6 and / or from 6-8 to greater than 8. Non-limiting examples of pH-sensitive dyes are described herein. Further examples of pH-sensitive dyes are known in the art.

[0068] Urine can be placed into a covered, transparent or semi-transparent sterile container (e.g., a first covered, transparent or semi-transparent sterile container and / or a second covered, transparent or semi-transparent sterile container) using a pipette. For example, a disposable plastic pipette or a plastic transfer pipette can be used to place urine into a covered, transparent or semi-transparent sterile container. In some embodiments, the methods described herein further include collecting urine from a subject.

[0069] In some embodiments, the method described herein further includes shaking any of the covered transparent or semi-transparent sterile containers described herein (e.g., a first covered transparent or semi-transparent sterile container and / or a second covered transparent or semi-transparent sterile container). For example, the first covered transparent or semi-transparent sterile container and / or the second covered transparent or semi-transparent sterile container may be shaken before determining the turbidity, acidity, or alkalinity of the urine in the first covered transparent or semi-transparent sterile container and / or the second covered transparent or semi-transparent sterile container. In some embodiments, the first covered transparent or semi-transparent sterile container and / or the second covered transparent or semi-transparent sterile container are shaken between steps (c) and (d).

[0070] In some embodiments, the method described herein further includes informing a physician that the subject has been diagnosed with a urinary tract infection. For example, such a method may include informing a physician that the subject has been diagnosed with a urinary tract infection and that the bacteria or fungus causing the urinary tract infection has been identified as sensitive to treatment with at least one antibiotic and / or at least one antifungal agent present in the second covered transparent or translucent sterile container.

[0071] In some embodiments, the method includes informing a physician that the subject has been diagnosed with a urinary tract infection and that the bacteria or fungus causing the urinary tract infection has been identified as insensitive to treatment with at least one antibiotic and / or at least one antifungal agent present in the second covered transparent or translucent sterile container.

[0072] In some implementations, such as those used herein, the time period is approximately 6 hours to approximately 48 hours. For example, the time periods used herein can be approximately 6 hours to approximately 42 hours, approximately 6 hours to approximately 36 hours, approximately 6 hours to approximately 30 hours, approximately 6 hours to approximately 24 hours, approximately 6 hours to approximately 18 hours, approximately 6 hours to approximately 12 hours, approximately 12 hours to approximately 48 hours, approximately 12 hours to approximately 42 hours, approximately 12 hours to approximately 36 hours, approximately 12 hours to approximately 30 hours, approximately 12 hours to approximately 24 hours, approximately 12 hours to approximately 18 hours, approximately 18 hours to approximately 48 hours, approximately 18 hours to approximately 42 hours, approximately 18 hours to approximately 36 hours, approximately 18 hours to approximately 30 hours, approximately 18 hours to approximately 24 hours, approximately 24 hours to approximately 48 hours, approximately 24 hours to approximately 42 hours, approximately 24 hours to approximately 36 hours, approximately 24 hours to approximately 30 hours, approximately 30 hours to approximately 48 hours, approximately 30 hours to approximately 42 hours, approximately 30 hours to approximately 36 hours, approximately 36 hours to approximately 48 hours, approximately 36 hours to approximately 42 hours, or approximately 42 hours to approximately 48 hours. In some implementations, the time period, as used herein, is about 12 hours to about 48 hours. In some implementations, the time period, as used herein, is about 12 hours to about 36 hours. In some implementations, the time period, as used herein, is about 6, about 12, about 18, about 24, about 36, or about 48 hours.

[0073] In some embodiments, incubation of covered transparent or semi-transparent sterile containers (e.g., a first covered transparent or semi-transparent sterile container and / or a second covered transparent or semi-transparent sterile container) is performed at a temperature of about 22ºC to about 37ºC. For example, incubation of covered transparent or semi-transparent sterile containers may be performed at temperatures of about 22ºC to about 36ºC, about 22ºC to about 34ºC, about 22ºC to about 32ºC, about 22ºC to about 30ºC, about 22ºC to about 28ºC, about 22ºC to about 26ºC, about 22ºC to about 24ºC, about 24ºC to about 36ºC, about 24ºC to about 34ºC, about 24ºC to about 32ºC, about 24ºC to about 30ºC, about 24ºC to about 28ºC, about 24ºC to about 26ºC, or about 26ºC. The incubation is performed at temperatures ranging from approximately 36ºC to approximately 34ºC, approximately 26ºC to approximately 32ºC, approximately 26ºC to approximately 30ºC, approximately 26ºC to approximately 28ºC, approximately 28ºC to approximately 36ºC, approximately 28ºC to approximately 34ºC, approximately 28ºC to approximately 32ºC, approximately 28ºC to approximately 30ºC, approximately 30ºC to approximately 36ºC, approximately 30ºC to approximately 34ºC, approximately 30ºC to approximately 32ºC, approximately 32ºC to approximately 36ºC, approximately 32ºC to approximately 34ºC, or approximately 34ºC to approximately 36ºC. In some embodiments, the incubation of covered transparent or translucent sterile containers is performed at temperatures ranging from approximately 22ºC to approximately 30ºC. In some embodiments, the incubation of covered transparent or translucent sterile containers is performed at temperatures ranging from approximately 22ºC to approximately 26ºC. In some implementations, the incubation of covered, transparent or semi-transparent sterile containers is carried out at temperatures of about 22ºC, about 24ºC, about 26ºC, about 28ºC, about 30ºC, about 32ºC, about 34ºC, or about 37ºC.

[0074] Other implementation plans

[0075] It should be understood that although the invention has been described in conjunction with specific embodiments thereof, the foregoing description is intended to illustrate rather than limit the scope of the invention, which is defined by the appended claims. Other aspects, advantages, and modifications are within the scope of the following claims.

Claims

1. A kit comprising: (a) A first covered, transparent or semi-transparent sterile container; and (b) A second covered, transparent or semi-transparent sterile container, the second container containing at least one antibiotic and / or at least one antifungal agent.

2. The kit according to claim 1, wherein the first covered transparent or translucent sterile container and the second covered transparent or translucent sterile container are made of glass.

3. The kit according to claim 1, wherein the first covered transparent or translucent sterile container and the second covered transparent or translucent sterile container are made of plastic.

4. The kit according to any one of claims 1-3, wherein the first covered transparent or semi-transparent sterile container and the second covered transparent or semi-transparent sterile container are flat-bottomed containers.

5. The kit according to any one of claims 1-3, wherein the first covered transparent or semi-transparent sterile container and the second covered transparent or semi-transparent sterile container are round-bottomed containers.

6. The kit according to any one of claims 1-5, wherein the first capped transparent or translucent sterile container and the second capped transparent or translucent sterile container comprise screw caps.

7. The kit of claim 6, wherein the screw cap comprises a filter or membrane with a pore size of about 0.03 micrometers to about 0.22 micrometers, the filter or membrane allowing air to enter and exit the first capped transparent or translucent sterile container and the second capped transparent or translucent sterile container.

8. The kit according to any one of claims 1-5, wherein the first covered transparent or translucent sterile container and the second covered transparent or translucent sterile container comprise snap-on caps.

9. The kit of claim 8, wherein the snap-on cap comprises a filter or membrane with a pore size of about 0.03 micrometers to about 0.22 micrometers, the filter or membrane allowing air to enter and exit the first capped transparent or translucent sterile container and the second capped transparent or translucent sterile container.

10. The kit according to any one of claims 1-9, wherein the internal volume of the first capped transparent or translucent sterile container and the second capped transparent or translucent sterile container is from about 0.2 mL to about 50 mL.

11. The kit of claim 10, wherein the internal volume of the first covered transparent or semi-transparent sterile container and the second covered transparent or semi-transparent sterile container is from about 0.5 mL to about 20 mL.

12. The kit according to claim 11, wherein the internal volume of the first covered transparent or semi-transparent sterile container and the second covered transparent or semi-transparent sterile container is about 1 mL to about 5 mL.

13. The kit according to any one of claims 1-12, wherein the height of the first covered transparent or translucent sterile container and the second covered transparent or translucent sterile container is from about 1.0 cm to about 20 cm.

14. The kit according to claim 13, wherein the height of the first covered transparent or translucent sterile container and the second covered transparent or translucent sterile container is from about 1.5 cm to about 15 cm.

15. The kit according to claim 14, wherein the height of the first covered transparent or translucent sterile container and the second covered transparent or translucent sterile container is from about 2 cm to about 10 cm.

16. The kit according to any one of claims 1-15, wherein the second capped transparent or translucent sterile container contains at least one antibiotic.

17. The kit according to claim 16, wherein the at least one antibiotic is present as a solid in the second capped transparent or translucent sterile container.

18. The kit according to claim 16, wherein the at least one antibiotic is present as a solution in the second capped transparent or translucent sterile container.

19. The kit according to any one of claims 16-18, wherein the at least one antibiotic is selected from: amoxicillin / clavulanic acid, ampicillin, ampicillin / sulbactam, cefazolin, cefepime, ceftriaxone, ciprofloxacin, ertapenem, fosfomycin, gentamicin, imipenem, levofloxacin, nitrofurantoin, PIP / tazobactam, tobramycin, and trimethoprim / sulfonamide sulfamethoxazole.

20. The kit according to any one of claims 16-19, wherein the at least one antibiotic is a single antibiotic.

21. The kit according to any one of claims 16-19, wherein the at least one antibiotic is two or more different antibiotics.

22. The kit according to any one of claims 1-15, wherein the second covered transparent or translucent sterile container contains at least one antifungal agent.

23. The kit according to claim 22, wherein the at least one antifungal agent is present as a solid in the second covered transparent or translucent sterile container.

24. The kit according to claim 22, wherein the at least one antifungal agent is present as a solution in the second capped transparent or translucent sterile container.

25. The kit according to any one of claims 22-24, wherein the at least one antifungal agent is selected from: fluconazole, caspofungin, anidoxuridine, voriconazole, amphotericin B, echinococcin, and azoles.

26. The kit according to any one of claims 22-25, wherein the at least one antifungal agent is a single antifungal agent.

27. The kit according to any one of claims 22-26, wherein the at least one antifungal agent is two or more different antifungal agents.

28. The kit according to any one of claims 1-15, wherein the second covered transparent or translucent sterile container comprises at least one antibiotic and at least one antifungal agent.

29. The kit according to any one of claims 1-28, wherein the kit further comprises a support.

30. The kit according to any one of claims 1-28, wherein the kit further comprises at least one additional covered transparent or translucent sterile container, the additional container comprising at least one antibiotic and / or at least one antifungal agent, the antibiotic and / or antifungal agent being different from the at least one antibiotic and / or at least one antifungal agent present in the second covered transparent or translucent sterile container.

31. A method for diagnosing a urinary tract infection in a subject and determining the susceptibility of the bacteria and / or fungi causing the urinary tract infection to antibiotics and / or antifungal agents, wherein the method comprises: (a) A volume of urine from the subject is placed into a first covered, transparent or semi-transparent sterile container; (b) A volume of urine from the subject is placed into a second covered, transparent or semi-transparent sterile container, the second container containing at least one antibiotic and / or at least one antifungal agent; (c) Incubate the first covered transparent or semi-transparent sterile container and the second covered transparent or semi-transparent sterile container for a certain period of time; (d) Determine the turbidity of the urine in the first covered transparent or semi-transparent sterile container and the second covered transparent or semi-transparent sterile container after the said time period; in: The presence of turbidity in the urine in the first covered transparent or semi-transparent sterile container after the specified time period indicates that the subject has a urinary tract infection, and the decrease in turbidity of the urine in the second covered transparent or semi-transparent container after the specified time period compared to the turbidity of the urine in the first covered transparent or semi-transparent sterile container after the specified time period indicates that the bacteria or fungus causing the urinary tract infection is sensitive to treatment with at least one antibiotic and / or at least one antifungal agent present in the second covered transparent or semi-transparent sterile container; The presence of turbidity in the urine in the first covered transparent or semi-transparent sterile container indicates that the subject has a urinary tract infection, and the similarity of turbidity in the urine in the second covered transparent or semi-transparent container to the turbidity in the first covered transparent or semi-transparent sterile container after the specified time period indicates that the bacteria or fungus causing the infection is not responsive to treatment with the at least one antibiotic and / or the at least one antifungal agent present in the second covered transparent or semi-transparent sterile container; or The absence of detectable turbidity in the urine in the first covered transparent or semi-transparent sterile container after the stated time period indicates that the subject does not have a urinary tract infection.

32. The method of claim 31, wherein the method further comprises collecting urine from the subject.

33. The method according to claim 31 or 32, wherein the placement in steps (a) and (b) includes the use of a pipette.

34. The method according to claim 33, wherein the pipette is a disposable plastic pipette.

35. The method according to any one of claims 31-34, wherein the method further comprises, between steps (c) and (d), shaking the first covered transparent or translucent sterile container and the second covered transparent or translucent sterile container.

36. The method according to any one of claims 31-35, wherein the subject is identified as having a urinary tract infection, and the bacteria or fungus causing the urinary tract infection is identified as being sensitive to treatment with the at least one antibiotic and / or the at least one antifungal agent present in the second covered transparent or translucent sterile container.

37. The method according to any one of claims 31-35, wherein the subject is identified as having a urinary tract infection, and the bacteria or fungus causing the urinary tract infection is identified as insensitive to treatment with the at least one antibiotic and / or the at least one antifungal agent present in the second covered transparent or translucent sterile container.

38. The method according to any one of claims 31-35, wherein the subject is identified as not having a urinary tract infection.

39. The method of claim 36 or 37, wherein the method further comprises notifying a physician that the subject has been diagnosed with a urinary tract infection.

40. The method of claim 36, wherein the method further comprises notifying a physician that the subject has been diagnosed with a urinary tract infection and that the bacteria or fungus causing the urinary tract infection has been identified as sensitive to treatment with the at least one antibiotic and / or the at least one antifungal agent present in the second covered transparent or translucent sterile container.

41. The method of claim 37, wherein the method further comprises notifying a physician that the subject has been diagnosed with a urinary tract infection and that the bacteria or fungus causing the urinary tract infection has been identified as insensitive to treatment with the at least one antibiotic and / or the at least one antifungal agent present in the second covered transparent or translucent sterile container.

42. The method according to any one of claims 31-41, wherein the time period is from about 6 hours to about 48 hours.

43. The method of claim 42, wherein the time period is from about 12 hours to about 48 hours.

44. The method of claim 43, wherein the time period is from about 12 hours to about 36 hours.

45. The method according to any one of claims 31-44, wherein the incubation in step (c) is carried out at a temperature of about 22ºC to about 37ºC.

46. ​​The method of claim 45, wherein the incubation in step (c) is carried out at a temperature of about 22ºC to about 30ºC.

47. The method of claim 46, wherein the incubation in step (c) is carried out at a temperature of about 22ºC to about 26ºC.

48. The method according to any one of claims 31-47, wherein the first covered transparent or translucent sterile container and the second covered transparent or translucent sterile container are made of glass.

49. The method according to any one of claims 31-47, wherein the first covered transparent or translucent sterile container and the second covered transparent or translucent sterile container are made of plastic.

50. The method according to any one of claims 31-49, wherein the first covered transparent or translucent sterile container and the second covered transparent or translucent sterile container are flat-bottomed containers.

51. The method according to any one of claims 31-49, wherein the first covered transparent or translucent sterile container and the second covered transparent or translucent sterile container are round-bottomed containers.

52. The method according to any one of claims 31-51, wherein the first covered transparent or translucent sterile container and the second covered transparent or translucent sterile container comprise screw caps.

53. The method of claim 52, wherein the screw cap comprises a filter or membrane with a pore size of about 0.03 micrometers to about 0.22 micrometers, the filter or membrane allowing air to enter and exit the first covered transparent or translucent sterile container and the second covered transparent or translucent sterile container.

54. The method according to any one of claims 31-51, wherein the first covered transparent or translucent sterile container and the second covered transparent or translucent sterile container comprise snap-on caps.

55. The method of claim 54, wherein the snap-on cap comprises a filter or membrane with a pore size of about 0.03 micrometers to about 0.22 micrometers, the filter or membrane allowing air to enter and exit the first capped transparent or translucent sterile container and the second capped transparent or translucent sterile container.

56. The method according to any one of claims 31-55, wherein the internal volume of the first covered transparent or translucent sterile container and the second covered transparent or translucent sterile container is from about 0.2 mL to about 50 mL.

57. The method of claim 56, wherein the internal volume of the first covered transparent or translucent sterile container and the second covered transparent or translucent sterile container is from about 0.5 mL to about 20 mL.

58. The method of claim 57, wherein the internal volume of the first covered transparent or translucent sterile container and the second covered transparent or translucent sterile container is about 1 mL to about 5 mL.

59. The method according to any one of claims 31-58, wherein the height of the first covered transparent or translucent sterile container and the second covered transparent or translucent sterile container is from about 1.0 cm to about 20 cm.

60. The method of claim 59, wherein the height of the first covered transparent or translucent sterile container and the second covered transparent or translucent sterile container is from about 1.5 cm to about 15 cm.

61. The method of claim 60, wherein the height of the first covered transparent or translucent sterile container and the second covered transparent or translucent sterile container is from about 2 cm to about 10 cm.

62. The method according to any one of claims 31-61, wherein the second covered transparent or translucent sterile container contains at least one antibiotic.

63. The method of claim 62, wherein the at least one antibiotic is present as a solid in the second covered transparent or translucent sterile container.

64. The method of claim 62, wherein the at least one antibiotic is present as a solution in the second capped transparent or translucent sterile container.

65. The method according to any one of claims 62-64, wherein the at least one antibiotic is selected from: amoxicillin / clavulanic acid, ampicillin, ampicillin / sulbactam, cefazolin, cefepime, ceftriaxone, ciprofloxacin, ertapenem, fosfomycin, gentamicin, imipenem, levofloxacin, nitrofurantoin, PIP / tazobactam, tobramycin, and trimethoprim / sulfonamide sulfamethoxazole.

66. The method according to any one of claims 62-65, wherein the at least one antibiotic is a single antibiotic.

67. The method according to any one of claims 62-65, wherein the at least one antibiotic is two or more different antibiotics.

68. The method according to any one of claims 31-61, wherein the second covered transparent or translucent sterile container contains at least one antifungal agent.

69. The method of claim 68, wherein the at least one antifungal agent is present as a solid in the second covered transparent or translucent sterile container.

70. The method of claim 68, wherein the at least one antifungal agent is present as a solution in the second covered transparent or translucent sterile container.

71. The method according to any one of claims 68-70, wherein the at least one antifungal agent is selected from: fluconazole, caspofungin, anidoxuridine, voriconazole, amphotericin B, echinococcin, and azoles.

72. The method according to any one of claims 68-71, wherein the at least one antifungal agent is a single antifungal agent.

73. The method according to any one of claims 68-71, wherein the at least one antifungal agent is two or more different antifungal agents.

74. The method according to any one of claims 31-61, wherein the second covered transparent or translucent sterile container comprises at least one antibiotic and at least one antifungal agent.